Prelude Therapeutics Incorporated
PRLDNASDAQHealthcare● Active
$3.99
+$0.15(+3.91%)
Market Cap$227161780
P/E Ratio—
52W High$5.54
52W Low$0.75
Prelude Therapeutics Incorporated (PRLD) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · PRLD · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $12.14M | $7.00M | $0.00M | $0.00M | $0.00M |
| Cost of Revenue | $1.71M | $0.00M | $0.00M | $0.00M | $0.00M |
| Gross Profit | $10.43M | $7.00M | $0.00M | $0.00M | $0.00M |
| Gross Margin %(computed) | 85.91% | 100.00% | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $94.30M | $118.00M | $103.39M | $92.89M | $86.78M |
| G&A Expenses | $22.41M | $28.72M | $28.88M | $30.65M | $26.96M |
| Total Operating Expenses | $115.00M | $146.71M | $132.28M | $123.54M | $113.73M |
| Operating Income | ($104.57M) | ($139.71M) | ($132.28M) | ($123.54M) | ($113.73M) |
| Operating Margin %(computed) | -861.33% | — | — | — | — |
| Interest Income | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | ($99.50M) | ($127.17M) | ($121.83M) | ($115.44M) | ($111.69M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($99.50M) | ($127.17M) | ($121.83M) | ($115.44M) | ($111.69M) |
| Net Margin %(computed) | -819.59% | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.29 | $-1.68 | $-2.02 | $-2.27 | $-2.33 |
| Wtd Avg Shares | 76.96M | 75.81M | 60.36M | 47.37M | 47.60M |
| EBITDA | ($102.86M) | ($137.94M) | ($131.11M) | ($122.22M) | ($112.82M) |
| EBITDA Margin %(computed) | -847.24% | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Prelude Therapeutics Incorporated data
About Prelude Therapeutics Incorporated (PRLD) Income Statement
Prelude Therapeutics Incorporated (PRLD) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, PRLD reported revenue of $0.01B, gross profit of $0.01B (gross margin 85.91%), and net income of ($0.10B) — a net profit margin of -819.59%.
Frequently asked questions
PRLD · 4 questionsPrelude Therapeutics Incorporated (PRLD) reported revenue of $0.01B for 2025, up 73.4% year-over-year.
PRLD revenuePRLD salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09